Glaxosmithkline Pharmaceuticals Ltd vs Natural Capsules Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2345 as of 04 May 11:02 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Natural Capsules Ltd changed from 9.7 on March 2021 to 307 on March 2025 . This represents a CAGR of 99.56% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Natural Capsules Ltd changed from ₹ 67.03 crore on March 2021 to ₹ 190.48 crore on March 2025 . This represents a CAGR of 23.23% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Natural Capsules Ltd for the Dec '25 is ₹ 38.19 crore as compare to the Sep '25 revenue of ₹ 45.96 crore. This represent the decline of -16.91% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Natural Capsules Ltd for the Dec '25 is ₹ -1.88 crore as compare to the Sep '25 ebitda of ₹ -0.72 crore. This represent the growth of 161.11% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Natural Capsules Ltd changed from ₹ 0.6 crore to ₹ -7.12 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Natural Capsules Ltd changed from 8.96 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Natural Capsules Ltd

Natural Capsules Limited was incorporated as Public Limited Company established in 1993 at Bangalore.
The Company is one of the leading manufacturers of hard capsule shells in India.
The Company introduced vegetarian capsules to Indian market and is the second-largest manufacturer of gelatin capsules in the country. Company expanded its operations to Puducherry in 2003, further solidifying its position as a trusted brand in the industry.
By venturing into API manufacturing under its subsidiary, Natural Biogenex Private Limited, Company presently operates two distinct business verticals-Capsules and APIs.
The company is a well-equipped modern manufacturing plant to manufacture Hard Gelatin Capsule shells, Hard Cellulose Capsule shells and Pharmaceutical Dosage Forms in Capsule Dosage Form.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Natural Capsules Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Natural Capsules Ltd is 159 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Natural Capsules Ltd stock price is INR ₹153.8.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Natural Capsules Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.